Dark Pool•Event Tuesday, October 12, 2021Analyzed

Sana Biotechnology

Bullish

Synthetic Biology & Intracellular mRNA Delivery

Summary

Sana Biotechnology has raised $703.4M in a Regulation D private placement (Form D filed 2026-06-02), with first sale in 2021-10-12. This is an enormous capital raise for a synthetic biology company focused on intracellular mRNA delivery, indicating very high investor demand in the private markets.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Full Analysis

### Executive Summary Sana Biotechnology has raised $703.4M in a Regulation D private placement (Form D filed 2026-06-02), with first sale in 2021-10-12. This is an enormous capital raise for a synthetic biology company focused on intracellular mRNA delivery, indicating very high investor demand in the private markets. ### Investor Edge Watch for any subsequent Form D/A amendments that may reveal the identity of the investors or changes in terms. The involvement of Shield Capital and Founders Fund as related persons suggests a deep tech/crossover fund profile. Compare this raise size to peers like Moderna's early rounds. ### Sector capital positioning The $703.4M raise signals intense private capital flow into synthetic biology and mRNA delivery platforms, even as public biotech markets have tightened. It suggests major institutional confidence in next-generation intracellular therapeutics. ### Convergence Signals No specific public signals (patents, contracts, legislation) are directly tied in the filing. However, the size and sector imply potential convergence with mRNA vaccine/drug delivery platforms and gene editing technologies. ### Key Takeaways - Sana Biotechnology raised $703.4M in a single private placement, one of the largest in synthetic biology. - Related persons include Shield Capital and Founders Fund, indicating top-tier VC backing. - The filing is a Form D (initial notice), not a D/A amendment, suggesting no prior SEC filing for this round. ### Risk Indicators & Flags The $703.4M amount is unusually large for a Form D, which may trigger SEC review. The absence of a first sale date change suggests the funds were raised over time. No D/A amendment filed yet, but watch for one. The sector is capital-intensive with long timelines to revenue. ### Verification & References This is a Regulation D private placement filing. SEC Accession: 0001702600-24-20291. Verify at SEC EDGAR: https://www.sec.gov/cgi-bin/browse-edgar?company=Sana%20Biotechnology&type=D&action=getcompany . No public ticker exists; company is private.